DelveInsight Evaluates a Robust RNA Interference Pipeline as Key 85+ Pharma Companies Set Foot in the RNA Interference Space

RNA interference clinical trial pipeline constitutes 85+ key companies continuously working towards developing 100+ RNA interference therapies, analyzes DelveInsight

LAS VEGAS, Nov. 1, 2022 /PRNewswire/ -- DelveInsight's 'RNA Interference Competitive Landscape – 2022' report provides comprehensive global coverage of available, marketed, and pipeline RNA interference therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the RNA interference competitive domain.

Key Takeaways from the RNA Interference Pipeline Report

• Over 85+ RNA interference companies are evaluating 100+ RNA interference pipeline therapies in various stages of development, and their anticipated acceptance in the RNA interference market would significantly increase market revenue. 
• Leading RNA interference companies such as Alnylam Pharmaceuticals, Suzhou Ribo Life Science, Arrowhead Pharmaceuticals, Sylentis, Vir Biotechnology, Arbutus Biopharma, Silenseed, OliX Pharmaceuticals, Bio-Path Holdings, Janssen Pharmaceuticals, Eli Lilly and Company, Dicerna Pharmaceuticals, Amgen, Sirnaomics, Silence Therapeutics, Sylentis, Silence Therapeutics, Suzhou Ribo Life Science, Phio Pharmaceuticals, Amylon Therapeutics, Aro Biotherapeutics, DTx Pharma, BONAC Corporation, and others are evaluating novel RNA interference drugs candidate to improve the treatment landscape.
• Key RNA interference pipeline therapies in various stages of development include SR061, ARO-APOC3, DCR-PHXC, SYL-1001, Fitusiran, Zilebesiran, VIR-2218, AB 729, Antisense K-ras RNA gene therapy, OLX 101A, Lumasiran, Prexigebersen-A, JNJ-3989, LY 3561774, DCR-HBVS, Olpasiran, STP705, ARO-HSD, ARO-MUC5AC, RBD1016, ANGPTL3 siRNA, SLN124, JNJ-75220795, LY3819469, ARO-HIF2, SYL 1801, STP707, DRC-AUD, SLN360, SR043, SR044, PH 894, PH 762PF-06650833, Polyoxidonium, Remimazolam, OP-101, Rayaldee, OT-101, ADM03820, OLT 1177, NVXCoV 2373, DFV890, Crizanlizumab, MAS-825, NBT-NM108, Ambrisentan, Sargramostim, Gam-COVID-Vac, mRNA-1283, MP1032, Molnupiravir, M5049, Covifenz, INOmax, MW33, RNA convalescent plasma, LB1148, Mavrilimumab, and others.
• In April 2022, Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for vutrisiran, an investigational RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. The FDA has set an action date of April 14, 2022, under the Prescription Drug User Fee Act (PDUFA), and the Agency has indicated that they are not currently planning an advisory committee meeting as part of the NDA review
• In November 2021, Arrowhead Pharmaceuticals Inc. announced that its collaborator, Janssen Pharmaceuticals, Inc., (Janssen) one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has disclosed its collaboration with Arrowhead on investigational compound JNJ-75220795, which is in a Phase I clinical study
• In November 2021, Arrowhead Pharmaceuticals announced that it entered into an exclusive license agreement with GSK under which GSK will develop and commercialize ARO-HSD.

Request a sample and discover the recent advances in RNA interference treatment @RNA Interference Competitive Landscape Report

RNA Interference Overview

RNA interference (RNAi) is one of several RNA silencing pathways that use small RNAs as guides for sequence-specific silencing. In C. elegans, RNAi was discovered and defined as sequence-specific mRNA degradation induced by long double-stranded RNA (dsRNA). RNA interference (RNAi) technology regulates mRNA stability and translation in nearly all human cells.

RNA interference (RNAi) is a conserved biological response to double-stranded RNA that mediates resistance to both endogenous parasitic and exogenous pathogenic nucleic acids and regulates the expression of protein-coding genes. This natural mechanism for sequence-specific gene silencing has the potential to transform experimental biology and may have significant practical applications in functional genomics, therapeutic intervention, agriculture, and other fields.

Find out more about RNA interference method @RNA Interference Technology

RNA Interference Pipeline Analysis: Drug Profile

ARO-APOC3: Arrowhead Pharmaceuticals

ARO-APOC3 is a subcutaneously administered RNAi therapeutic that inhibits the production of Apolipoprotein C-III (Apoc-III), a component of triglyceride-rich lipoproteins (TRLs) such as VLDL and chylomicrons, as well as a key regulator of triglyceride metabolism. The company believes that decreasing Apoc-III hepatic production will result in decreased VLDL synthesis and assembly, improved TRL breakdown, and improved clearance of VLDL and chylomicron remnants. It is currently being researched as a possible treatment for severe hypertriglyceridemia (SHTG), familial chylomicronemia syndrome (FCS), and mixed dyslipidemia. Arrowhead's RNA interference (RNAi) therapeutic is currently in phase III testing for FCS and phase II testing for mixed dyslipidemia and SHTG.

DCR-HBVS: Dicerna Pharmaceuticals

DCR-HBVS is a GalXC RNAi therapy being developed by Roche for the treatment of chronic hepatitis B virus (HBV) infection. Chronic HBV increases the risk of developing liver failure, cancer, or cirrhosis, a condition that scars the liver permanently. DCR-HBVS has the potential to contribute to the ultimate goal of achieving a functional cure in chronic HBV patients and is currently being studied by Roche as part of Phase II clinical trial in combination with other treatment regimens to induce functional cures in patients. Furthermore, it is being tested in phase I for chronic hepatitis B.

A snapshot of the RNA Interference Pipeline Drugs mentioned in the report:

Learn more about the emerging RNA interference pipeline therapies @RNA Interference Clinical Trials

Scope of the RNA Interference Competitive Landscape Report 

• Coverage: Global 
• Key RNA Interference Companies: Alnylam Pharmaceuticals, Suzhou Ribo Life Science, Arrowhead Pharmaceuticals, Sylentis, Vir Biotechnology, Arbutus Biopharma, Silenseed, OliX Pharmaceuticals, Bio-Path Holdings, Janssen Pharmaceuticals, Eli Lilly and Company, Dicerna Pharmaceuticals, Amgen, Sirnaomics, Silence Therapeutics, Sylentis, Silence Therapeutics, Suzhou Ribo Life Science, Phio Pharmaceuticals, Amylon Therapeutics, Aro Biotherapeutics, DTx Pharma, BONAC Corporation, and others
• Key RNA Interference Pipeline Therapies: SR061, ARO-APOC3, DCR-PHXC, SYL-1001, Fitusiran, Zilebesiran, VIR-2218, AB 729, Antisense K-ras RNA gene therapy, OLX 101A, Lumasiran, Prexigebersen-A, JNJ-3989, LY 3561774, DCR-HBVS, Olpasiran, STP705, ARO-HSD, ARO-MUC5AC, RBD1016, ANGPTL3 siRNA, SLN124, JNJ-75220795, LY3819469, ARO-HIF2, SYL 1801, STP707, DRC-AUD, SLN360, SR043, SR044, PH 894, PH 762PF-06650833, Polyoxidonium, Remimazolam, OP-101, Rayaldee, OT-101, ADM03820, OLT 1177, NVXCoV 2373, DFV890, Crizanlizumab, MAS-825, NBT-NM108, Ambrisentan, Sargramostim, Gam-COVID-Vac, mRNA-1283, MP1032, Molnupiravir, M5049, Covifenz, INOmax, MW33, RNA convalescent plasma, LB1148, Mavrilimumab, and others.

Dive deep into rich insights for drugs for RNA interference treatment; visit @RNA Interference Medicine

Table of Contents

For further information on the RNA interference pipeline therapeutics, reach out @RNA Interference Therapy

Related Reports

Global Messenger RNA Market

Global Messenger RNA Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key global messenger RNA companies, including Moderna, Inc., BioNTech SE, CureVac N.V., Arcturus Therapeutics, Translate Bio, Inc., GSK, among others.

Global Messenger RNA Epidemiology

Global Messenger RNA Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted global messenger RNA epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Viral RNA Polymerase Inhibitor Pipeline

Viral RNA Polymerase Inhibitor Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key viral RNA polymerase inhibitor companies, including Beta Pharma, Merck & Co, Gilead Sciences, Anadys Pharmaceuticals, Can-Fite BioPharma, among others.

Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market

Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key global messenger RNA -based vaccines and therapeutics companies, including Moderna, Inc., BioNTech SE, CureVac N.V., Arcturus Therapeutics, Translate Bio, Inc., GSK, among others.

DNA-Dependent RNA Polymerase Inhibitor Pipeline

DNA-Dependent RNA Polymerase Inhibitor Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key DNA-dependent RNA polymerase inhibitor companies, including Silence Therapeutics, Sylentis, Silence Therapeutics, Suzhou Ribo Life Science, Phio Pharmaceuticals, Amylon Therapeutics, Aro Biotherapeutics, among others.

Other Trending Reports

Goitre Market |  Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | Chimeric Antigen Receptor (CAR) T-Cell Therapy Market | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Report | Crows Feet Market | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market | Insulin Glargine Biosimilar Insight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. 

Connect with us at LinkedIn 

Contact Us

Shruti Thakur  
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg